A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease

Deferasirox is a once-daily, oral iron chelator developed for treating transfusional iron overload. Preclinical studies indicated that the kidney was a potential target organ of toxicity. As patients with sickle cell disease often have abnormal baseline renal function, the primary objective of this...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Vichinsky, Elliott, Onyekwere, Onyinye, Porter, John, Swerdlow, Paul, Eckman, James, Lane, Peter, Files, Beatrice, Hassell, Kathryn, Kelly, Patrick, Wilson, Felicia, Bernaudin, Françoise, Forni, Gian Luca, Okpala, Iheanyi, Ressayre-Djaffer, Catherine, Alberti, Daniele, Holland, Jaymes, Marks, Peter, Fung, Ellen, Fischer, Roland, Mueller, Brigitta U, Coates, Thomas
Формат: Artigo
Язык:Inglês
Опубликовано: Blackwell Publishing Ltd 2007
Предметы:
Red Cells and Iron
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC1974786/
https://ncbi.nlm.nih.gov/pubmed/17233848
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2006.06455.x
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы